Tag: GlobeNewswire

NEW YORK, Oct. 05, 2026 (GLOBE NEWSWIRE) — Serve Robotics Inc. (Nasdaq: SERV), a leader in autonomous robotics, announced that on Wednesday, October 7, 2026, Ali Kashani, Co-Founder and Chief Executive Officer, and Brian Read, Chief Financial Officer, will host one-on-one meetings with investors at Evercore ISI’s 5th Annual Automation Tech & Physical AI Conference in New York.

Investors interested in connecting with Serve management at the conference may contact investors.relations@serverobotics.com.

For more information, please visit the Company’s Investor Relations website at investors.serverobotics.com.

About Serve

Serve Robotics (Nasdaq: SERV) designs and operates autonomous robots that navigate complex, human-centric environments. Since spinning off from Uber in 2021, Serve has deployed more than 2,000 robots across the U.S., reaching a population of approximately 3 million and supporting delivery for more than 4,000 restaurants. In 2026, Serve acquired Diligent Robotics, expanding its operations beyond sidewalk delivery into indoor service robots used in hospitals. Serve designs both the hardware and software behind its robots, enabling them to work safely in public and private environments at scale.

For more information, visit www.serverobotics.com or follow the company on X, Instagram, and LinkedIn @serverobotics.

Forward Looking Statements

This press release contains “forward-looking statements,” within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the context of the statement and generally arise when we or our management are discussing our beliefs, estimates or expectations. Such statements generally include the words “believes,” “plans,” “intends,” “targets,” “may,” “could,” “should,” “will,” “expects,” “estimates,” “suggests,” “anticipates,” “outlook,” “continues,” or similar expressions. These statements are not historical facts or guarantees of future performance, but represent management’s belief at the time the statements were made regarding future events which are subject to certain risks, uncertainties and other factors, many of which are outside of our control. Actual results and outcomes may differ materially from what is expressed or forecast in such forward-looking statements.

The forward-looking statements contained in this press release are also subject to other risks and uncertainties, including those more fully described in our filings with the Securities and Exchange Commission (“SEC”), including in the sections entitled “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our Annual Report on Form 10-K for the year ended December 31, 2025, as supplemented by the sections entitled “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our Quarterly Report on Form 10-Q for the quarter ended June 30, 2026, and in the Company’s subsequent SEC filings. The Company can give no assurance that the plans, intentions, expectations or strategies as reflected in or suggested by those forward-looking statements will be attained or achieved. The forward-looking statements in this press release are based on information available to the Company as of the date hereof, and the Company disclaims any obligation to update any forward-looking statements, except as required by law. These forward-looking statements should not be relied upon as representing the Company’s views as of any date subsequent to the date of this press release.

OCALA, Fla., Oct. 05, 2026 (GLOBE NEWSWIRE) — AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today highlighted recent media coverage of the antiviral potential of Ampligen^® (rintatolimod), the Company’s investigational dsRNA and highly selective TLR3 agonist immunomodulator.

• Healthcare Business Today: AIM ImmunoTech CEO Tom Equels on Why Broad-Spectrum Antiviral Preparedness Cannot Wait for the Next Outbreak
• MediTech Today: What AIM ImmunoTech’s New Long COVID Patent Protection Says About the Future of Post-Viral Therapeutics

The recent coverage reflects growing attention around Ampligen’s potential broad-spectrum antiviral and biodefense preparedness applications, including the drug’s possible role against emerging viral and post-viral threats such as Ebola Virus Disease, as well as the continued expansion of AIM’s intellectual property portfolio in Long COVID and other antiviral applications.

The coverage has emphasized the broad-spectrum antiviral potential of Ampligen, which research shows enhances the body’s innate immune response, enabling it to fight back against a diverse range of viral threats – and perhaps even stave off initial infections by dangerous diseases. Clinical trials suggest that Ampligen’s broad-spectrum immune effect is also the reason for its potential as a therapy against a range of solid tumors, including pancreatic cancer, which is the focus of AIM’s oncology clinical program.

“I am a true believer in the proposition that a strong innate response is vitally important,” said AIM Chief Executive Officer Thomas K. Equels. “Recent media coverage underscores the important role that a broad-spectrum antiviral such as Ampligen could serve in preparing for potential viral threats before they grow into very real outbreaks. We believe Ampligen’s broad-spectrum antiviral potential, together with the continued expansion of our intellectual property estate in Long COVID and other post-viral applications, supports a differentiated opportunity across preparedness and public health. We remain focused on advancing the body of evidence around Ampligen and protecting its potential applications.”

About AIM ImmunoTech Inc.

AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of its lead product, Ampligen^® (rintatolimod), for the treatment of late-stage pancreatic cancer, a lethal and unmet global health problem. Ampligen is a dsRNA and highly selective TLR3 agonist immuno-modulator that has shown broad-spectrum activity in clinical trials.

For more information, please visit aimimmuno.com and connect with the Company on X, LinkedIn, and Facebook.

Cautionary Statement

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that involve a number of risks and uncertainties. Any forward-looking statements set forth in this press release speak only as of the date hereof. Such forward-looking statements may include statements relating, but not limited to: the potential of Ampligen to address viral and post-viral threats, and the Company’s ability to create long-term value for its stockholders. Forward-looking statements include statements attributed to, or made by, the Company’s Chief Executive Officer in this press release. For all forward-looking statements, the Company claims the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. All statements in this press release other than statements of historical fact, including statements regarding the potential of Ampligen’s mechanism of action, anticipated regulatory milestones, our future results of operations and financial position, our business strategy and plans, and our objectives for future operations, are forward-looking statements. Words such as “believe,” “may,” “might,” “will,” “could,” “should,” “can,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “envision,” “potential” and similar expressions are intended to identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. The Company does not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof, except as required by applicable law. The Company is in various stages of seeking to determine whether Ampligen will be effective in the treatment of multiple types of viral diseases, cancers, and immune-deficiency disorders, and disclosures in the Company’s reports filed with the SEC, on its website, and in its press releases set forth its current and anticipated future activities. These activities are subject to change for a number of reasons. Significant additional testing and trials will be required to determine whether Ampligen® will be effective in the treatment of these conditions. Results obtained in preclinical studies do not necessarily predict results in humans. Human clinical trials will be necessary to prove whether or not Ampligen® will be efficacious in humans. No assurance can be given as to whether current or planned clinical trials will be successful or yield favorable data, and the trials are subject to many factors including lack of regulatory approval(s), lack of study drug, lack of adequate funding, or a change in priorities at the institutions sponsoring other trials. Even if these clinical trials are initiated, the Company cannot assure that the clinical studies will be successful or yield any useful data. No assurance can be given that the findings in preliminary studies will prove true or that such studies will yield favorable results, or that future studies will not result in findings that are different from those reported in the studies referenced in the Company’s reports filed with the SEC, on the Company’s website, and in its press releases. Operating in foreign countries carries with it a number of risks, including potential difficulties in enforcing intellectual property rights. The Company cannot assure that its potential foreign operations will not be adversely affected by these risks.

For a detailed discussion of these and other risk factors, please review the “Risk Factors” section in the Company’s most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q filed with the U.S. Securities and Exchange Commission. These filings are available at www.sec.gov and www.aimimmuno.com. You should not place undue reliance on any forward-looking statements. The information found on the Company’s website or on other websites referenced or linked to in this press release is not incorporated by reference into this press release and such information is referenced or linked for reference purposes only.

CONTACT: Investor Contact:

JTC Team, LLC
Jenene Thomas
908.824.0775
AIM@jtcir.com

Preliminary Fiscal Q4 2026 Product Revenue of $3.8 Million

Preliminary Full-Year Product Revenue Up 15.6% to $10.5 Million, at the Top of Guidance Range

EDEN PRAIRIE, Minn., Oct. 05, 2026 (GLOBE NEWSWIRE) — NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) (“NeuroOne” or the “Company”), a medical technology company dedicated to transforming the surgical diagnosis and treatment of neurological disorders, today announced preliminary, unaudited product revenue for its fourth fiscal quarter and full fiscal year ended September 30, 2026, and provided an update on recent product orders.

NeuroOne expects to report fourth quarter fiscal 2026 product revenue of approximately $3.8 million, representing year-over-year growth of 38.4%, compared to approximately $2.7 million in the fourth quarter of fiscal 2025. For the full fiscal year 2026, the Company expects to report revenue of approximately $10.5 million, representing 15.6% year-over-year growth and landing at the top of its previously announced revenue guidance range of $9.2 million to $10.5 million.

In September 2026, NeuroOne secured a $4.5 million product purchase order, the largest in the Company’s history. Approximately $1.0 million of the order shipped in September 2026, with shipments of the remaining $3.6 million expected to begin during the first quarter of fiscal 2027 and into the second quarter of fiscal 2027, subject to manufacturing and delivery schedules. Following receipt of this order, total open purchase orders for shipments through the first quarter of fiscal 2027 increased to $5.4 million as of September 30, 2026. This record purchase order provides greater visibility into anticipated product shipments, cash flow and revenue opportunities as the Company enters fiscal 2027.

“Momentum continues to build across our business,” said Dave Rosa, Chief Executive Officer of NeuroOne. “We are happy to report that product orders increased 24.2% in fiscal 2026 compared to fiscal 2025. We enter fiscal 2027 from a position of strength supported by $5.4 million in open purchase orders and we are also very well positioned with additional growth drivers including the commercialization of our trigeminal neuralgia system, international market expansion, and the advancement of our drug delivery platform.”

Complete financial results for the fourth quarter and full fiscal year 2026 are expected to be announced in December 2026, in conjunction with the filing of the Company’s Annual Report on Form 10-K with the Securities and Exchange Commission.

The selected unaudited financial results included in this press release are preliminary and subject to the completion of year-end accounting and audit procedures and are therefore subject to adjustment. This preliminary financial information is the responsibility of management and has been prepared in good faith on a basis consistent with prior periods. As a result, prospective investors should exercise caution in relying on this information and should not draw any inferences regarding the Company’s financial information that is not provided. This preliminary financial information should not be viewed as a substitute for complete financial statements prepared in accordance with United States generally accepted accounting principles.

About NeuroOne

NeuroOne Medical Technologies Corporation is a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders. NeuroOne markets a minimally invasive and high-definition/high-precision electrode technology platform with four FDA-cleared product families: Evo® Cortical Electrodes, Evo® sEEG Electrodes, OneRF® Ablation System (for brain), and OneRF® Trigeminal Nerve Ablation System. These solutions offer the potential to reduce the number of hospitalizations and surgical procedures, lower costs, and improve patient outcomes by offering diagnostic and therapeutic functions. The Company is engaged in research and development for drug delivery, basivertebral nerve ablation and spinal cord stimulation programs. For more information, visit nmtc1.com.

Forward Looking Statements

This press release may include forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Except for statements of historical fact, any information contained in this press release may be a forward–looking statement that reflects NeuroOne’s current views about future events and are subject to known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. In some cases, you can identify forward–looking statements by the words or phrases “may,” “might,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “objective,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “target,” “seek,” “contemplate,” “continue”, “focused on,” “committed to” and “ongoing,” or the negative of these terms, or other comparable terminology intended to identify statements about the future. Forward–looking statements may include statements regarding the fourth quarter and full fiscal year 2026 revenue amounts, international market expansion, and the launch of our drug delivery program. Although NeuroOne believes that we have a reasonable basis for each forward-looking statement, we caution you that these statements are based on a combination of facts and factors currently known by us and our expectations of the future, about which we cannot be certain. Our actual future results may be materially different from what we expect due to factors largely outside our control, including risks that our partnerships may not facilitate the commercialization or market acceptance of our technology; whether due to supply chain disruptions, labor shortages, risks that our technology will not perform as expected based on results of our pre-clinical and clinical trials; risks related to uncertainties associated with the Company’s capital requirements to achieve its business objectives and ability to raise additional funds: the risk that we may not be able to secure or retain coverage or adequate reimbursement for our technology; uncertainties inherent in the development process of our technology; risks related to changes in regulatory requirements or decisions of regulatory authorities; that we may not have accurately estimated the size and growth potential of the markets for our technology; risks related to our ability to protect our intellectual property rights; and other risks, uncertainties and assumptions, including those described under the heading “Risk Factors” in our filings with the Securities and Exchange Commission. These forward–looking statements speak only as of the date of this press release and NeuroOne undertakes no obligation to revise or update any forward–looking statements for any reason, even if new information becomes available in the future.

Company Contact:
800-631-4030
ir@nmtc1.com

Investor Relations:
MZ Group – MZ North America
949-491-8235

NMTC@mzgroup.us

BALTIMORE, Oct. 05, 2026 (GLOBE NEWSWIRE) — Sinclair, Inc. (Nasdaq: SBGI) will report its third quarter 2026 earnings results at 4:00 p.m. ET on Wednesday, November 4, 2026, followed by a conference call to discuss the results at 4:30 p.m. ET.

The call will be webcast live and can be accessed at www.sbgi.net under the subtitle “Investor Relations/Events and Presentations.” The dial-in number for the earnings call is 877-545-0523, with entry code 437861.

If you plan to participate on the conference call, please call at least two minutes prior to the start time and provide the entry code to the conference operator; or tell the operator that you are joining the Sinclair Earnings Conference Call.

If you are unable to listen to the live webcast or participate in the live conference call, a replay of the call will be available on Sinclair’s website at www.sbgi.net. This will be the only venue through which a replay will be available. The company’s press release and any non-GAAP reconciliations will also be available on the website.

Members of the news media are welcome on the call in a listen-only mode. Key executives will be made available to members of the news media, time permitting, following the conference call.

The Company regularly uses its website as a key source of Company information and can be accessed at www.sbgi.net.

Category: Financial

Investor Contacts:

Christopher C. King, VP, Investor Relations

(410) 568-1500

Stockholm, 5th of October 2026 – Virtune AB (Publ) (“Virtune”) today announces that it has completed the monthly rebalancing of the Virtune Crypto Altcoin Index ETP, listed on Nasdaq Stockholm, Nasdaq Helsinki, Xetra and Warsaw Stock Exchange (ISIN code SE0023260716).

In addition to the Virtune Crypto Altcoin Index ETP, Virtune’s product portfolio includes:

Virtune Arbitrum ETP
Virtune Avalanche ETP
Virtune Bitcoin ETP
Virtune Bitcoin Prime ETP
Virtune Bittensor ETP
Virtune BNB ETP
Virtune Chainlink ETP
Virtune Coinbase 50 Index ETP
Virtune Crypto Top 10 Index ETP EUR
Virtune Crypto Top 10 Index ETP SEK
Virtune Hyperliquid ETP
Virtune Litecoin ETP
Virtune Polygon ETP
Virtune Stablecoin Index ETP
Virtune Staked Cardano ETP
Virtune Staked Ethereum ETP
Virtune Staked NEAR ETP
Virtune Staked Polkadot ETP
Virtune Staked Solana ETP
Virtune Stellar ETP
Virtune Sui ETP
Virtune XRP ETP

Index allocation as of 29 September 2026 (before rebalancing):

Bitcoin Cash: 11.11%
Chainlink: 11.08%
Solana: 10.86%
Cardano: 10.07%
Stellar: 9.91%
XRP: 9.79%
Canton: 9.78%
Hyperliquid: 9.47%
BNB: 9.26%
Gram: 8.68%

Index allocation as of 30th of September (after rebalancing):

Canton: 10.00%
Cardano: 10.00%
Bitcoin Cash: 10.00%
BNB: 10.00%
Solana: 10.00%
Stellar: 10.00%
XRP: 10.00%
Hyperliquid: 10.00%
Chainlink: 10.00%
Litecoin: 10.00%

In connection with this month’s rebalancing, Gram (GRAM) is exiting the index and Litecoin (LTC) is entering the index.

The performance of the Virtune Crypto Altcoin Index ETP for September was +15.39%.

The rebalancing is carried out according to the index that the ETP tracks, the Virtune Crypto Altcoin Index. The purpose of the monthly rebalancing is to reset the weights of each crypto asset to provide equal-weighted exposure to altcoins.

Virtune Crypto Altcoin Index ETP is the first of its kind in the Nordic region. It includes up to 10 leading alternative crypto assets (altcoins), excluding Bitcoin and Ethereum. Each altcoin is equally weighted to promote diversification; this structure allows investors to gain broad exposure to crypto assets beyond Bitcoin and Ethereum without being heavily concentrated in any single crypto asset.

If you, as an (institutional) investor, are interested in meeting with Virtune to explore how our ETPs can support your asset management strategy or to learn more about Virtune and our product offering, please feel free to contact us at hello@virtune.com. You can also visit www.virtune.com to learn more and subscribe to our newsletter for updates on upcoming ETP launches and other news related to digital assets.

Press contact
Christopher Kock, CEO Virtune AB (Publ)
christopher@virtune.com
+46 70 073 45 64

Virtune with its headquarters in Stockholm is a regulated Swedish digital asset manager and issuer of crypto exchange traded products on regulated European exchanges. With regulatory compliance, strategic collaborations with industry leaders and our proficient team, we empower investors on a global level to access innovative and sophisticated investment products that are aligned with the evolving landscape of the global crypto market.

Cryptocurrency investments are associated with high risk. Virtune does not provide investment advice. Investments are made at your own risk. Securities may increase or decrease in value, and there is no guarantee that you will recover your invested capital. Please read the prospectus, KID, terms at www.virtune.com.

Pilot follows extensive adaptation of the Jupiter product line to meet end customer-specific video streaming requirements, with potential for broader deployment

Rehovot, Israel, Oct. 05, 2026 (GLOBE NEWSWIRE) — Maris-Tech Ltd. (Nasdaq: MTEK, MTEKW) (“Maris-Tech” or the “Company”), a global leader in edge computing, artificial intelligence (“AI”), and video intelligence solutions for defense applications, today announced that it has received a pilot order for an armored vehicle situational awareness application from a leading global defense company. The order was received through a distributor.

The pilot follows an extensive engineering and adaptation process in which Maris-Tech’s Jupiter product line was adapted to meet the end customer’s specific video streaming requirements for armored vehicle situational awareness.

The adaptations developed to address these requirements have expanded the capabilities of Maris-Tech’s products that the Company believes may also support additional applications and market opportunities across the modern battlefield.

Based on estimates and forecasts provided by the end customer, successful completion of the pilot could result in significant follow-on orders over the coming years.

“This pilot represents the result of a substantial engineering process focused on meeting the specific video requirements of a major defense customer,” said Israel Bar, Chief Executive Officer of Maris-Tech. “We believe that beyond the potential opportunity with this customer, the capabilities developed through this process strengthen the versatility of our Jupiter product line and expand its relevance to additional armored vehicle and battlefield applications.”

About Maris-Tech Ltd.

Maris-Tech delivers AI-powered edge video solutions for mission-critical defense and security operations, enabling real-time situational awareness, intelligence gathering, and surveillance in bandwidth- and latency-constrained environments. Trusted by leading security organizations, Maris-Tech platforms are deployed across UAVs, UGVs, armored vehicles, and dismounted soldier systems, supporting missions that require ultra-low-latency video processing and onboard AI analytics. From intelligence collection in extreme conditions to AI-driven surveillance and terrain dominance, Maris-Tech masters the AI video pipeline at the edge through best-in-class SWaP-optimized, ruggedized computing solutions.

For more information, visit https://www.maris-tech.com/

Forward-Looking Statements Disclaimer

This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that are intended to be covered by the “safe harbor” created by those sections. Forward-looking statements, which are based on certain assumptions and describe the Company’s future plans, strategies and expectations, can generally be identified by the use of forward-looking terms such as “believe,” “expect” “may”, “should,” “could,” “seek,” “intend,” “plan,” “goal,” “estimate,” “anticipate” or other comparable terms. For example, the Company is using forward-looking statements when it is discussing the advantages, benefits and capabilities of the Jupiter product line, its belief that the added capabilities of the Jupiter product line may also support additional applications and market opportunities across the modern battlefield, the potential for successful completion of the pilot to result in significant follow-on orders over the coming years and the Company’s belief that beyond the potential opportunity with this customer, the capabilities developed through this process strengthen the versatility of its Jupiter product line and expand its relevance to additional armored vehicle and battlefield applications. The Company’s actual results and financial condition may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause the Company’s actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the following: its ability to successfully market its products and services, including in the United States; the acceptance of its products and services by customers; its continued ability to pay operating costs and ability to meet demand for its products and services; the amount and nature of competition from other security and telecom products and services; the effects of changes in the cybersecurity and telecom markets; its ability to successfully develop new products and services; its success establishing and maintaining collaborative, strategic alliance agreements, licensing and supplier arrangements; its ability to comply with applicable regulations; and the other risks and uncertainties described in the Annual Report on Form 20-F for the year ended December 31, 2025, filed with the SEC on May 15, 2026, and its other filings with the Securities and Exchange Commission. The Company undertakes no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

Investor Relations:

Nir Bussy, CFO
Tel: +972-72-2424022
Nir@maris-tech.com

VANCOUVER, British Columbia, Oct. 05, 2026 (GLOBE NEWSWIRE) — SHARC International Systems Inc. (CSE: SHRC) (FSE: IWIA) (OTCQB: INTWF) (“SHARC Energy” or the “Company”) is pleased to announce that its Board of Directors has approved grants of stock options and restricted share units (“RSUs”) pursuant to the Company’s equity incentive plans.

The Company has granted an aggregate of 9,590,000 stock options to certain directors, officers and eligible participants of the Company. Each option is exercisable at a price of $0.09 per common share, vests immediately and expires on October 2, 2029, subject to the terms of the Company’s Stock Option Plan and applicable grant documentation.

The Company has also granted an aggregate of 1,806,250 RSUs to non-executive employees pursuant to the Company’s Restricted Share Unit Plan. The RSUs will vest four months following the date of grant, subject to the terms of the RSU Plan and applicable award agreements.

The equity grants are intended to align the interests of the Company’s directors, management and employees with the long-term interests of shareholders and form part of the Company’s ongoing compensation and retention program.

About SHARC Energy  

SHARC International Systems Inc. is a world leader in energy recovery from the wastewater we send down the drain every day. SHARC Energy’s systems recycle thermal energy from wastewater, generating one of the most energy-efficient and economical systems for heating, cooling & hot water production for commercial, residential, and industrial buildings along with thermal energy networks, commonly referred to as “District Energy”.

SHARC Energy is publicly traded in Canada (CSE: SHRC), the United States (OTCQB: INTWF) and Germany (Frankfurt: IWIA) and you can find out more on our SEDAR profile.

Learn more about SHARC Energy: Website | Investor Page | LinkedIn | YouTube | PIRANHA | SHARC

ON BEHALF OF THE BOARD

Fred Andriano
Chairman

The Canadian Securities Exchange does not accept responsibility for the adequacy or accuracy of this release.

Forward-Looking Statements 

Certain statements contained in this news release may constitute forward-looking information. Forward-looking information is often, but not always, identified using words such as “anticipate”, “plan”, “estimate”, “expect”, “may”, “will”, “intend”, “should”, and similar expressions. Forward-looking information involves known and unknown risks, uncertainties and other factors that may cause actual results or events to differ materially from those anticipated in such forward-looking information. SHARC Energy’s actual results could differ materially from those anticipated in this forward-looking information because of regulatory decisions, competitive factors in the industries in which the Company operates, prevailing economic conditions, and other factors, many of which are beyond the control of the Company. SHARC Energy believes that the expectations reflected in the forward-looking information are reasonable, but no assurance can be given that these expectations will prove to be correct and such forward-looking information should not be unduly relied upon. Any forward-looking information contained in this news release represents the Company’s expectations as of the date hereof and is subject to change after such date. The Company disclaims any intention or obligation to update or revise any forward-looking information whether because of new information, future events or otherwise, except as required by applicable securities legislation. 

CONTACT: For investor inquiries, please contact:
Shane Dungey
Chief Executive Officer (SHARC Energy)
Telephone: 403.389.9911
Email: shane.dungey@sharcenergy.com

For media inquiries, please contact:
John Louis Fahie
Marketing Director
SHARC Energy
Telephone: 403.808.0882
Email: johnlouis.fahie@sharcenergy.com

Company Announcement No. 1173

This financial calendar lists the expected dates of publication of financial announcements and the Annual General Meeting in the 2027 financial year for DSV A/S:

2 February 2027	Annual Report 2026
18 March 2027	Annual General Meeting 2027. Any proposals for the agenda of the Annual General Meeting must be received no later than 3 February 2027.
21 April 2027	Interim Financial Report, First Quarter 2027
21 July 2027	Interim Financial Report, H1 2027
27 October 2027	Interim Financial Report, Third Quarter 2027

Contacts
Investor Relations
Stig Frederiksen, tel. +45 43 20 36 38, stig.frederiksen@dsv.com
Alexander Plenborg, tel. +45 43 20 33 73, alexander.plenborg@dsv.com

Yours sincerely,
DSV A/S

Attachment

• 1173 – Announcement (05.10.2026) – FINANCIAL CALENDAR 2027

• Combination broadens iRhythm’s cardiac monitoring portfolio, advances its multi-vitals strategy and expands iRhythm’s addressable market across the continuum of care.
• iRhythm’s commercial scale, health system relationships, market access expertise, and integrated clinical service capabilities are expected to accelerate VitalConnect’s growth and expand customer access.
• Transaction is expected to enhance iRhythm’s revenue growth rate beginning in 2027 while preserving iRhythm’s previously communicated 15% adjusted EBITDA margin target for 2027.

SAN FRANCISCO, Oct. 05, 2026 (GLOBE NEWSWIRE) — iRhythm Holdings, Inc. (Nasdaq: IRTC) today announced that it completed the previously announced acquisition of Vital Connect, Inc. (“VitalConnect”), a leader in wearable biosensor technology and ambulatory cardiac monitoring.

“Today marks an important milestone as iRhythm continues its evolution toward a broader cardiac monitoring and intelligence platform,” said Quentin Blackford, President and Chief Executive Officer of iRhythm. “VitalConnect brings complementary mobile cardiac telemetry (MCT), multi-vitals and monitoring capabilities to iRhythm’s established end-to-end cardiac monitoring service. Together, we can offer clinicians greater choice, serve more patients and customers across the continuum of care, and deepen customer relationships. We are pleased to welcome the VitalConnect team to iRhythm.”

“Joining iRhythm creates an opportunity to extend the reach and impact of VitalConnect’s technology,” said Peter Van Haur, Chief Executive Officer of VitalConnect. “By bringing together what our team has built with iRhythm’s scale, clinical expertise and customer reach, we believe we can accelerate the growth of our platform, expand access to our technology and create even greater value for clinicians and patients.”

VitalConnect’s cardiac monitoring platform supports multiple modalities, including complementary MCT capabilities. The VitalConnect platform offers differentiated features such as up to 30-day patient monitoring, four-in-one functionality, flexible service models and live look-in. VitalConnect’s platform also has the capability to monitor up to 11 physiological parameters, advancing iRhythm’s multi-vitals strategy beyond traditional ambulatory cardiac monitoring. Together with iRhythm’s end-to-end cardiac monitoring service, the combination creates a broader portfolio designed to serve distinct customer workflows as well as clinician and patient needs.

Strategic Fit and Financial Benefit

The acquisition immediately expands iRhythm’s capabilities across ambulatory cardiac monitoring, including MCT, creating a broader portfolio to serve diverse clinical needs. The combination also creates meaningful commercial acceleration opportunities by leveraging iRhythm’s scale, customer relationships and go-to-market capabilities.

Further, the addition of VitalConnect broadens iRhythm’s addressable market across the continuum of care, extending its reach into inpatient, remote and hospital-to-home settings. The transaction also brings together complementary technology, data and workflow capabilities that are expected to accelerate innovation and enhance customer solutions. Together, these benefits strengthen iRhythm’s long-term growth profile and position the company to serve more clinicians, customers and patients across a broader range of care settings.

As previously announced, the acquisition is expected to enhance iRhythm’s revenue growth rate, while preserving its previously communicated adjusted EBITDA margin target of 15% for 2027.

Transaction Detail

The purchase consideration consisted of $237.5 million in cash, subject to customary adjustments, funded from iRhythm’s balance sheet and up to 423,334 shares issued in connection with closing. In addition, iRhythm provided $10.0 million of working capital funding to VitalConnect between signing and closing.

iRhythm will provide updated 2026 financial guidance, inclusive of VitalConnect, during its third quarter earnings call on November 5^th, 2026.

About iRhythm Holdings, Inc.

iRhythm is a leading digital health care company with a mission to boldly innovate to create trusted solutions that detect, predict, and prevent disease. Combining its Zio® wearable biosensors and cloud-based data analytics with powerful proprietary algorithms, iRhythm distills data from millions of heartbeats into clinically actionable information. Through a relentless focus on patient care, iRhythm’s vision is to deliver better data, better insights, and better health for all. For more information, visit www.irhythmtech.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, among other things, statements regarding the anticipated strategic, commercial, operational and financial benefits of the transaction; the ability to expand into new markets, care settings, customer categories and commercial partnerships; the potential to take advantage of and accelerate VitalConnect’s growth, deepen customer relationships and realize cross-selling opportunities; future product development, regulatory approvals and commercialization; the success of integration and the retention of key employees; the anticipated growth of the mobile cardiac telemetry category; and the expected impact on revenue growth, adjusted EBITDA and adjusted EBITDA margin. These statements may be identified by words such as “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “project,” “should,” “target,” “will” and similar expressions. Forward-looking statements are based on current assumptions and expectations and involve risks and uncertainties that could cause actual results to differ materially, including challenges in integrating VitalConnect and realizing anticipated benefits and synergies on the expected timeline or at all; business disruption or diversion of management’s attention; changes in market demand, reimbursement, competition or regulation; product development or regulatory delays; the loss of key VitalConnect employees, customers or partners; and unforeseen liabilities and future expenditures associated with the transaction; and the risks described under “Risk Factors” and elsewhere in iRhythm’s filings with the Securities and Exchange Commission, including its Quarterly Report on Form 10-Q filed on August 6, 2026. These forward-looking statements speak only as of the date of this press release. iRhythm undertakes no obligation to update them except as required by law.

Contacts

Investors	Media
Francis Pruell investors@irhythmtech.com	Kassandra Perry mediarelations@irhythmtech.com

Ghost Face, Billy the Puppet, Jason Voorhees, and Pinhead get a fashion-forward makeover this spooky season

SANTA MONICA, Calif., Oct. 05, 2026 (GLOBE NEWSWIRE) — JAKKS Pacific, Inc. (NASDAQ: JAKK), a leading global designer, manufacturer and marketer of toys and consumer products, is debuting Doll Haus of Dread™, a bold new collector fashion doll line that transforms horror’s most feared figures into high-style, display-worthy collectibles.

Launching exclusively at Walmart and Walmart.com in Fall 2026, this is horror fandom reimagined by one stitch, one slash, and one sinister silhouette at a time.

The debut lineup features dolls inspired by four of cinema’s most chilling icons: Ghost Face® as seen in the motion picture Scream, Billy the Puppet from Saw, Jason from Jason Universe franchise and Pinhead from Hellraiser. Each 11-inch fashion doll is crafted for collectors who want their shelves to scream style, featuring franchise-authentic fashions, signature accessories and nine points of articulation for striking poses as sharp and unforgettable as the characters themselves.

“With Doll Haus of Dread™, we’re reimagining some of horror’s most legendary figures as collectible works of art, blending authentic franchise storytelling with elevated fashion, sculptural detail, and artistic interpretation. Each doll is carefully crafted to honor the DNA of its respective property while introducing fresh creative perspectives that resonate with both horror enthusiasts and collectors. These aren’t simply dolls, they’re celebrations of the characters, films, and cultural impact that have defined the genre for decades. Doll Haus of Dread™ invites fans to experience horror icons in an entirely new way, where artistry, craftsmanship, and terror coexist beautifully,” said Dominick Lisi, Senior Vice President of Marketing at JAKKS Pacific.

JAKKS Pacific’s Doll Haus of Dread™ lives in the details–where elevated design meets cinematic dread through beautifully crafted dolls with meticulously styled accessories. Inspired by some of the films’ most iconic moments, our Jason Universe doll arrives in a slasher and summer camp-themed aesthetic complete with a signature hockey mask. While Pinhead commands the room in a Cenobite-inspired gown. Billy the Puppet steps out in a signature pinstripe tuxedo suit. Two Ghost Face dolls are available, one classic with the hooded silhouette that’s haunted screens for decades and a limited-edition version, available exclusively at Walmart.com, that wears a new bling encrusted mask.

Each doll retails for $39.97 and will hit shelves just in time for spooky season because nothing is more haunting than dolls dressed to kill.

Doll Haus of Dread™ marks the first chapter in a broader vision for Doll Haus as a unified collector destination. Beyond this debut collection, Doll Haus will expand into a house of sub-collections spanning fandom-driven properties, exclusive entertainment collections, and powerful collaborations, all designed to build a lifestyle destination for collectors rather than a single product line. As the platform grows, JAKKS plans to deepen the collector experience through direct-to-consumer exclusives, behind-the-scenes content, and a growing presence at conventions and events.

Visit dollhaushq.com for more information and follow @dollhaushq on Instagram and TikTok for the latest updates. Find Doll Haus of Dread™ at Walmart and Walmart.com this fall.

About JAKKS Pacific, Inc.:
JAKKS Pacific, Inc. is a leading designer, manufacturer and marketer of toys and consumer products sold throughout the world, with its headquarters in Santa Monica, California. JAKKS Pacific’s popular proprietary brands include Disguise®, Fly Wheels®, Charming™, Kidtopia™, Moose Mountain®, Maui®, ReDo® Skateboard Co., Sky Ball®, and Xtreme Power Dozer® as well as a wide range of entertainment-inspired products featuring premier licensed properties. Through their products and charitable donations, JAKKS is helping to make a positive impact on the lives of children. Visit us at www.jakks.com and follow us on Instagram (@jakkspacific.toys), X (@jakkstoys), YouTube (@JAKKSPacific), Facebook (@jakkspacific.toys) and LinkedIn (JAKKS Pacific).

Scream (2022) ⓒ 2026 Paramount Pictures. All Rights Reserved.

Ghost Face® Fun World Div., Easter Unlimited Inc. All Rights Reserved.

JASON UNIVERSE TM & Mask ⓒ Horror, Inc.

®, ™ & ⓒ 2026 Lions Gate Entertainment Inc. All Rights Reserved

‘Hellraiser™ Park Ave. Ent.
© 2026 Park Ave Ent. LLC & Clive Barker Ink, Inc.

Media Contact:
JAKKS Pacific
Jessica Kavanaugh
publicrelations@jakks.net

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/a622d77e-3197-43d1-9c95-e6141c1aee11